title: [Symptomatic hypokalemia caused by meglumine antimoniate].
authors.forename: S
authors.initials: S
authors.lastname: Bouvresse
authors.forename: E
authors.initials: E
authors.lastname: Matichard
authors.forename: E
authors.initials: E
authors.lastname: Mahé
authors.forename: E
authors.initials: E
authors.lastname: Marinho
authors.forename: A
authors.initials: A
authors.lastname: Soria
authors.forename: M
authors.initials: M
authors.lastname: Devillière
authors.forename: V
authors.initials: V
authors.lastname: Descamps
authors.forename: B
authors.initials: B
authors.lastname: Crickx
mesh_terms: D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007008:Hypokalemia / Q000139:chemically induced*; D007273:Injections, Intramuscular; D007896:Leishmaniasis / Q000188:drug therapy*; D008536:Meglumine / Q000008:administration & dosage / Q000009:adverse effects*; D000077485:Meglumine Antimoniate; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate